Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
Daiichi Sankyo
Baxter
QuintilesIMS
Citi
Moodys
Fish and Richardson
Deloitte

Generated: May 25, 2018

DrugPatentWatch Database Preview

LOZOL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Lozol patents expire, and when can generic versions of Lozol launch?

Lozol is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOZOL is indapamide. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the indapamide profile page.
Summary for LOZOL
Drug patent expirations by year for LOZOL
Medical Subject Heading (MeSH) Categories for LOZOL
Synonyms for LOZOL
(+/-)-4-CHLORO-N-(2-METHYL-1-INDOLINYL)-3-SULFAMOYLBENZAMIDE
(+/-)-Indapamide
(4-chloro-3-sulfamoylphenyl)-N-(2-methylindolinyl)carboxamide
1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline
26807-65-8
3-(Aminosulfonyl)-4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)benzamide
3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide
3-(aminosulphonyl)-4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1--yl)benzamide
3-(aminosulphonyl)-4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)benzamide
3-aminosulfonyl-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide
4-chloro-3-aminosulphonyl-N-(2,3-dihydro2-methyl-1H-indol-1-yl)benzamide
4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzenecarboximidic acid
4-Chloro-N-(2-methyl-2,3-dihydro-indol-1-yl)-3-sulfamoyl-benzamide
4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
4-chloro-N-(2-methylindolin-1-yl)-3-sulfamoyl-benzamide
4-CHLORO-N-(2-METHYLINDOLIN-1-YL)-3-SULFAMOYLBENZAMIDE
49564-58-1
5-20-06-00348 (Beilstein Handbook Reference)
807I658
A23574
AB00052021
AB00052021_16
AB00052021_17
AB00052021-14
AB00052021-15
AB0012132
AB03037
AB2000254
AC-2073
AC1L1GIW
ACN-029813
AK163539
AKOS015888148
AN-14323
API0002990
Apo-Indapamide
Arifon
Arifon;Fludex;Noranat;Veroxil;Tertensif;Lozol
ARONIS27110
Bajaten
BDBM25901
Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-
Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI)
Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-(9CI)
Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-l-yl)-
BENZAMIDE, 4-CHLORO-N-(2-METHYL-1-INDOLINYL)-3-SULFAMOYL-
BPBio1_000263
BRD-A95869247-001-04-6
BRN 1604026
BSPBio_000239
BSPBio_002174
C-21015
C16H16ClN3O3S
CC-29500
CCG-40198
CHEBI:5893
CHEMBL406
CI-045
Cormil
CPD000058829
CS-2245
CTK3J2161
D00345
D0H8FH
Damide
DB00808
DivK1c_000508
DSSTox_CID_24633
DSSTox_GSID_44633
DSSTox_RID_80366
DTXSID7044633
EINECS 248-012-7
FLUBEST
Fludex
flupamid
FT-0630528
GTPL7203
HE064827
HE330316
HMS1920F19
HMS2090M16
HMS2091N07
HMS2095L21
HMS2231G13
HMS3259C14
HMS3369J20
HMS3655E06
HMS501J10
HY-B0259
Hypen SR
I01-0369
I0730
IDAMIDE
Idapamide
IDI1_000508
Indaflex
indamide
Indamol
Indapamid
Indapamida
Indapamida [INN-Spanish]
indapamide
Indapamide (JAN/USP)
Indapamide (JP17/USP)
Indapamide (Lozol)
Indapamide (USP)
Indapamide [USAN:INN:BAN:JAN]
Indapamide [USAN:USP:INN:BAN:JAN]
Indapamide 1.0 mg/ml in Methanol
Indapamide hemihydrate
Indapamide, analytical standard, for drug analysis
Indapamide, European Pharmacopoeia (EP) Reference Standard
Indapamide, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Indapamide, United States Pharmacopeia (USP) Reference Standard
INDAPAMIDE, USP
Indapamidum
Indapamidum [INN-Latin]
Ipamix
J-016554
J10257
KBio1_000508
KBio2_001397
KBio2_003965
KBio2_006533
KBio3_001394
KBioGR_000393
KBioSS_001397
KS-00000ZZ7
KS-000048LJ
KS-5219
Lozide
Lozol (TN)
LS-26138
MCULE-1549472772
Metindamide
MFCD00079375
MLS000028554
MLS001148152
MLS002222229
MLS006011900
MolPort-003-666-209
N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline
N-[4-Chloro-3-sulfamoylbenzamido]-2- methylindoline
N-[4-Chloro-3-sulfamoylbenzamido]-2-methylindoline
N-[4-CHLORO-3-SULFAMOYLBENZAMIDOL]-2-METHYLINDOLINE
Natrilix
Natrilix (TN)
Natrix
Natrix (TN)
NC00568
NCGC00018172-02
NCGC00018172-03
NCGC00018172-04
NCGC00018172-06
NCGC00018172-08
NCGC00018172-09
NCGC00089727-02
NCGC00089727-03
NCGC00256884-01
NDDAHWYSQHTHNT-UHFFFAOYSA-N
NINDS_000508
NLozol
NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide
Noranat
Novo-Indapamide
NSC-757075
NSC757075
Nu-Indapamide
Opera_ID_110
Pharmakon1600-01500349
Pressurai
Prestwick3_000220
RAC INDAPAMIDE
RHC 2555
RT-000328
S-1520
s1730
SAM002564214
SBI-0051415.P003
SC-22596
SCHEMBL41303
SE 1520
SE-1520
SMR000058829
SPBio_001019
Spectrum_000917
SPECTRUM1500349
Spectrum2_000980
Spectrum3_000467
Spectrum4_000017
Spectrum5_000866
SR-01000003079
SR-01000003079-2
ST51015024
STL257105
STL455045
Tandix
Tertensif
TL8002131
Tox21_110775
Tox21_110775_1
Tox21_113182
Tox21_302687
USV 2555
Veroxil
Z2786158257

US Patents and Regulatory Information for LOZOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us LOZOL indapamide TABLET;ORAL 018538-002 Apr 29, 1993 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us LOZOL indapamide TABLET;ORAL 018538-001 Jul 6, 1983 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Healthtrust
Merck
Cerilliant
Medtronic
Chubb
Fuji
Julphar
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.